title: The in vitro effects of remifentanil and fentanyl on isolated human right atria and saphenous veins.
abstract: OBJECTIVE
  To determine the myocardial and vascular effects of remifentanil and fentanyl in human atria and saphenous veins.
  
  
  METHODS
  In vitro, prospective with repeated measures.
  
  
  METHODS
  University research laboratory.
  
  
  METHODS
  The direct effects of remifentanil and fentanyl on the electrical stimulation-induced contraction of nonfailing human atrium and saphenous veins contracted with 5-hydroxytryptamine were studied.
  
  
  RESULTS
  In human atrial trabeculae, cumulative (10(-9)-10(-5) mol/L) added remifentanil had no effect on contractile force, compared with untreated muscles (p > 0.05). The force of contraction was significantly less than control values with concentrations of fentanyl ranging from 10(-8) to 10(-5) mol/L (p < 0.05). At the highest concentration (10(-5) mol/L), the inhibition by fentanyl of the electrical stimulation-induced contraction was 40.6% +/- 6.32%. In human saphenous vein strips preconstricted with 5-hydroxytryptamine, remifentanil (10(-8)-10(-5) mol/L) and fentanyl (10(-8)-10(-5) mol/L) produced "concentration-dependent" relaxation when compared with the control contraction value (p < 0.05). The IC(50) was similar with remifentanil and fentanyl and the E(max) of fentanyl was significantly higher than remifentanil (p < 0.05). The venodilatory effects of remifentanil and fentanyl were similar on veins with or without endothelium (p > 0.05).
  
  
  CONCLUSIONS
  Remifentanil has no direct effect on the contraction of myocardium. Fentanyl inhibits the electrical stimulation-induced contraction in human right atrial muscles in vitro. Remifentanil and fentanyl produce "concentration-dependent" relaxation in human saphenous vein strips independent from the endothelium.
authors.affiliation: Department of Anesthesiology and Intensive Care, University of Selcuk, Konya, Turkey. atesduman@hotmail.com
authors.forename: Ates
authors.initials: A
authors.lastname: Duman
authors.forename: Ayse
authors.initials: A
authors.lastname: Saide Sahin
authors.forename: Kismet
authors.initials: K
authors.lastname: Esra Atalik
authors.forename: Cemile
authors.initials: C
authors.lastname: öZtin ögün
authors.forename: Hasan
authors.initials: H
authors.lastname: Basri Ulusoy
authors.forename: Kadir
authors.initials: K
authors.lastname: Durgut
authors.forename: Selmin
authors.initials: S
authors.lastname: öKesli
mesh_terms: D000328:Adult; D000368:Aged; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000503:physiopathology / Q000628:therapy; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage / Q000627:therapeutic use*; D016166:Free Radical Scavengers / Q000627:therapeutic use; D006325:Heart Atria / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D000077208:Remifentanil; D015203:Reproducibility of Results; D012501:Saphenous Vein / Q000187:drug effects*; D012701:Serotonin / Q000627:therapeutic use; D013318:Stroke Volume / Q000502:physiology; D013997:Time Factors; D016896:Treatment Outcome; D014664:Vasodilation / Q000187:drug effects
chemical_list: D000701:Analgesics, Opioid; D016166:Free Radical Scavengers; D010880:Piperidines; D012701:Serotonin; D000077208:Remifentanil; D005283:Fentanyl